EUVIMEDEUVIMED entdecken
Crossref

Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy

Lu-Yi Yu, Pei-Wei Shueng, Hsin-Cheng Chiu iD, Yu-Wei Yen, Tzu-Yu Kuo, Chieh-Ru Li, Ming-Wei Liu, Chia-Hsin Ho, Tzu-Hao Ho, Bo-Wei Wang, Cheng-En Li, Ming-Hung Chen und 2 weitere

ACS Nano · 25.07.2023 · 17 (14) · 13158-13175

DOI: 10.1021/acsnano.2c12123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 12.07.2023. Verfasst von Lu-Yi Yu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, ROC. Hauptthemen laut MEDLINE: Hypoxia, Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Far Eastern Memorial Hospital, National Yang-Ming University, Ministry of Science and Technology, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour hypoxia plays an important role in modulating tumorigenesis, angiogenesis, invasion, immunosuppression, resistance to treatment, and even maintenance of the stemness of cancer stem cells (CSCs). Moreover, the targeting and treatment of hypoxic cancer cells and CSCs to reduce the influence of tumor hypoxia on cancer therapy remains an imperative clinical problem that needs to be addressed. Since cancer cells upregulate the expression of glucose transporter 1 (GLUT1) through the Warburg effect, we considered the possibility of GLUT1-mediated transcytosis in cancer cells and developed a tumor hypoxia-targeting nanomedicine. Our experimental results indicate that glucosamine-labeled liposomal ceramide can be efficiently transported between cancer cells by GLUT1 transporters and substantially accumulated in the hypoxic area in in vitro CSC spheroids and in vivo tumor xenografts. We also verified the effects of exogenous ceramide on tumor hypoxia, including important bioactivities such as upregulation of p53 and retinoblastoma protein (RB), downregulation of hypoxia-inducible factor-1 alpha (HIF-1α) expression, disruption of the OCT4-SOX2 network of stemness, and inhibition of CD47 and PD-L1 expression. To achieve an ideal therapeutic outcome, we combined treatment of glucosamine-labeled liposomal ceramide with paclitaxel and carboplatin, and we found an excellent synergistic effect, with tumor clearance being noted in three-fourths of the mice. Overall, our findings provide a potential therapeutic strategy for the treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoxiaNeoplasmsHumansMiceAnimalsGlucose Transporter Type 1Cell HypoxiaLiposomesNeoplastic Stem CellsTranscytosisHypoxia-Inducible Factor 1, alpha SubunitCell Line, Tumor

Stichwörter der Autor:innen

cancer stem cellsceramideglucose transporterhypoxia-targetingtranscytosis

Substanzen

Glucose Transporter Type 1LiposomesHypoxia-Inducible Factor 1, alpha Subunit

Autor:innen und Institutionen

  • Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, ROC.
  • Division of Radiation Oncology, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan, ROC.
  • Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, ROC.
  • Department of Biomedical Engineering and Environmental Sciences, National Tsing-Hua University, Hsinchu 300, Taiwan, ROC.
  • Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan, ROC.
  • Medical Device Innovation and Translation Center, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, ROC.

ORCID-Profile: Hsin-Cheng Chiu, Chun-Liang Lo

Förderung

  • Far Eastern Memorial Hospital
  • National Yang-Ming University
  • Ministry of Science and Technology, Taiwan

Zitieren

APA

Yu, L. Y., Shueng, P. W., Chiu, H. C., Yen, Y. W., Kuo, T. Y., Li, C. R., Liu, M. W., Ho, C. H., Ho, T. H., Wang, B. W., Li, C. E., Chen, M. H., Shen, Y. A., & Lo, C. L. (2023). Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy. ACS Nano, 17(14), 13158-13175. https://doi.org/10.1021/acsnano.2c12123

Vancouver

Yu LY, Shueng PW, Chiu HC, Yen YW, Kuo TY, Li CR, et al. Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy. ACS Nano. 2023;17(14):13158-13175. doi:10.1021/acsnano.2c12123

BibTeX
@article{Yu2023,
  author = {Yu, Lu-Yi and Shueng, Pei-Wei and Chiu, Hsin-Cheng and Yen, Yu-Wei and Kuo, Tzu-Yu and Li, Chieh-Ru and Liu, Ming-Wei and Ho, Chia-Hsin and Ho, Tzu-Hao and Wang, Bo-Wei and Li, Cheng-En and Chen, Ming-Hung and Shen, Yao-An and Lo, Chun-Liang},
  title = {Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy},
  journal = {ACS Nano},
  year = {2023},
  volume = {17},
  number = {14},
  pages = {13158--13175},
  doi = {10.1021/acsnano.2c12123}
}
Kostenlos starten →